AveXis (NASDAQ:AVXS) had its target price increased by analysts at Credit Suisse Group from $139.00 to $170.00 in a research report issued on Monday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s price target would suggest a potential downside of 18.89% from the stock’s current price.
A number of other research analysts have also weighed in on AVXS. Mizuho reissued a “neutral” rating on shares of AveXis in a report on Monday. William Blair assumed coverage on shares of AveXis in a report on Monday. They issued a “hold” rating for the company. ValuEngine upgraded AveXis from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Canaccord Genuity set a $110.00 price target on AveXis and gave the stock a “hold” rating in a research report on Friday, January 5th. Finally, BidaskClub downgraded AveXis from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $125.45.
AVXS stock opened at $209.60 on Monday. AveXis has a fifty-two week low of $65.23 and a fifty-two week high of $209.60. The firm has a market capitalization of $4,256.84, a P/E ratio of -28.79 and a beta of 2.05.
AveXis (NASDAQ:AVXS) last posted its earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91). research analysts predict that AveXis will post -7.63 EPS for the current year.
In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $126.19, for a total transaction of $224,618.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $119.50, for a total value of $1,792,500.00. Following the sale, the insider now owns 1,767,766 shares of the company’s stock, valued at $211,248,037. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,780 shares of company stock valued at $8,341,178. Corporate insiders own 18.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of AveXis by 57.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after purchasing an additional 453 shares during the last quarter. QS Investors LLC bought a new stake in shares of AveXis during the fourth quarter worth $156,000. Cubist Systematic Strategies LLC lifted its position in shares of AveXis by 688.6% during the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of AveXis during the third quarter worth $224,000. Finally, Vident Investment Advisory LLC bought a new stake in shares of AveXis during the third quarter worth $245,000. Institutional investors and hedge funds own 82.43% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AveXis (AVXS) PT Raised to $170.00 at Credit Suisse Group” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/avexis-avxs-pt-raised-to-170-00-at-credit-suisse-group.html.
AveXis Company Profile
AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.